Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets

Abstract

Purpose

A fixed-dose combination (FDC) of fimasartan and atorvastatin is used to treat hypertension and dyslipidemia. The peak plasma concentration (C_max) of fimasartan and atorvastatin has a large intra-subject variability with a maximum coefficient of variation of 65% and 48%, respectively. Therefore, both drugs are classified as highly variable drugs. The purpose of this study was to compare the pharmacokinetics (PK) between a FDC of fimasartan 120 mg and atorvastatin 40 mg versus separate tablets in healthy male Korean subjects.

Subjects and Methods

A randomized, single-dose, two-treatment, three-sequence, three-period, partial replicated crossover study was conducted with a 7-day washout interval between periods. Blood samples for fimasartan and atorvastatin were collected until 48 hours after administration in each period. PK parameters were calculated using the non-compartmental method. Geometric mean ratios (GMRs) for PK parameters of FDC to loose combination and their 90% confidence intervals (90% CIs) were estimated.

Results

A total of 56 subjects completed the study. GMRs (90% CIs) of the C_max for fimasartan and atorvastatin were 1.08 (0.93–1.24) and 1.02 (0.92–1.13), respectively. The expanded 90% CIs of both drugs using the intra-subject variability was calculated range of 0.70–1.43 and 0.73–1.38, respectively. The corresponding values of area under the concentration–time curve from zero to the last measurable time point were 1.02 (0.97–1.08) and 1.02 (0.98–1.07), respectively.

Conclusion

FDC of fimasartan 120 mg and atorvastatin 40 mg between their loose combination showed similar PK characteristics.

Keywords:

• fixed-dose combination
• partial replicated design
• fimasartan
• atorvastatin
• pharmacokinetics

Acknowledgments

The abstract of this paper was presented was presented at the 2018 annual meeting of ASCPT (American Society for Clinical Pharmacology and Therapeutics) as a poster presentation with interim findings. The abstract of this paper was published in “Volume 103, Issue S1” in Clinical Pharmacology and Therapeutics.

Disclosure

Dr Jun Gi Hwang reports grants from Boryung Pharmaceutical CO., LTD, during the conduct of the study. The authors report no other conflicts of interest in this work.